SCHEMBL6312574

SCHEMBL6312574

CC(=O)Oc1ccc2c(c1)[C@@]1(C)CCC[C@@](C)(C(=O)O)[C@@H]1CC2

nearest known ligand 0.82

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 7/20 0.82
NR1H3 Q13133 7/20 0.82
POLA1 P09884 4/20 0.79
PDE4D Q08499 1/20 0.63
KARS1 Q15046 2/20 0.58
RXRA P19793 1/20 0.58
CCNE1 P24864 1/20 0.58
CDK2 P24941 1/20 0.58
RXRB P28702 1/20 0.58
RXRG P48443 1/20 0.58
POLB P06746 1/20 0.57
APEX1 P27695 1/20 0.57
CYP2C9 P11712 1/20 0.55
TSHR P16473 1/20 0.55
CYP2C19 P33261 1/20 0.55
CYP3A4 P08684 1/20 0.55
PTPN1 P18031 1/20 0.54
NR1I2 O75469 1/20 0.53
OPRK1 P41145 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6312566 1.00 NR1H2 (0.82) NR1H2NR1H3POLA1PDE4DKARS1
Acetyl Podocarpic Acid Anhydride SCHEMBL31364127 0.90 NR1H2 (1.00) NR1H2NR1H3POLA1PDE4DCYP2C9
Acetyl Podocarpic Acid Anhydride SCHEMBL5538089 0.90 NR1H2 (1.00) NR1H2NR1H3POLA1PDE4DCYP2C9
SCHEMBL5510769 0.88 POLA1 (1.00) NR1H2NR1H3POLA1PDE4DKARS1
SCHEMBL12872352 0.88 POLA1 (1.00) NR1H2NR1H3POLA1PDE4DKARS1
SCHEMBL280198 0.88 POLA1 (1.00) NR1H2NR1H3POLA1PDE4DKARS1
SCHEMBL6312546 0.85 NR1H2 (0.72) NR1H2NR1H3POLA1PDE4DKARS1
SCHEMBL6312549 0.85 NR1H2 (0.72) NR1H2NR1H3POLA1PDE4DKARS1
SCHEMBL20560979 0.83 POLA1 (0.73) NR1H2NR1H3POLA1PDE4DKARS1
SCHEMBL2983955 0.82 NR1H2 (0.69) NR1H2NR1H3POLA1PDE4DKARS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6908934-B2 Therapeutic compounds for treating dyslipidemic conditions MERCK & CO., INC. (US) 2005-06-21 US disclosed
US-20030125357-A1 Therapeutic compounds for treating dyslipidemic conditions MERCK & CO., INC. 2003-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030125357-A1 Therapeutic compounds for treating dyslipidemic conditions NR1H2, NR1H3, APOB NR1H2 1/4885NR1H3 2/4885POLA1 3183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.